Weatherford International's rise in ROCE and decrease in capital employed suggest enhanced efficiency in generating returns. The substantial total return over the past three years signals investors' anticipation of more positive future performance.
Weatherford International's high P/S ratio isn't justified given its below-industry projected revenue growth. The company's current price levels and not so promising growth outlook warrant investor caution. Future disappointment is possible if P/S falls to match the growth outlook.
Market Summary 15/8/2023 August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the$ARK Innovation ETF(ARKK.US)$ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
Weatherford國際股票討論區
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US)$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
2022前三季度營收增長16.5%,營業利潤增長3倍到2.7億,但由於高昂的利息費用和非核心費用,扣稅後淨利潤爲虧損0.25億,少數股東又拿走0.21億,最後普通股股民承擔0.46億的虧損。
目前看不到投資價值。
• $DBV Technologies(DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $美第奇新星生物技術(MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US)$ +11% (In reaction to earnings/guidance)
• $諾瓦瓦克斯醫藥(NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
• $Seres Therapeutics(MCRB.US)$ : Jefferies Upgrades to Buy from Hold
• $法拉利(RACE.US)$ : Kepler Upgrades to Hold from Reduce
Downgrades
• $Dutch Bros(BROS.US)$ : JPMorgan Downgrades to Neutral from Overweight - PT $40
• $Canopy Growth(CGC.US)$ : BMO Capital Downgrades to Underperform from Market Perform - PT Cdn$2.50 (from Cdn$6)
• $Cazoo(CZOO.US)$ : Citigroup Downgrades to Neutral from Buy - PT $1.50 (from $9)
• $查特工業(GTLS.US)$ : Barcla...
暫無評論